We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+31.78%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$232M
AUM Growth
+$30.7M
Cap. Flow
-$28.5M
Cap. Flow %
-12.3%
Top 10 Hldgs %
46.06%
Holding
89
New
6
Increased
22
Reduced
19
Closed
10

Top Buys

Rank Stock Value
1
WVE icon
Wave Life Sciences
WVE
+$5.79M
2
SAGE
Sage Therapeutics
SAGE
+$2.82M
3
ALDR
Alder Biopharmaceuticals
ALDR
+$2.27M
4
MRSN
Mersana Therapeutics
MRSN
+$2.03M
5
BPMC
Blueprint Medicines
BPMC
+$2M

Top Sells

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$25.4M
2
NXTM
NxStage Medical Inc.
NXTM
+$8.93M
3
ASND icon
Ascendis Pharma A/S
ASND
+$2.88M
4
ARGX icon
argenx
ARGX
+$2.66M
5
KURA icon
Kura Oncology
KURA
+$1.73M

Sector Composition

Rank Sector Weight
1 Healthcare 88.92%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FOMX
26
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$3.03M 1.31%
808,000
– –
TVRD
27
Tvardi Therapeutics
TVRD
$19.7M
$2.82M 1.22%
3,989
– –
INDP icon
28
Indaptus Therapeutics
INDP
$172M
$2.8M 1.21%
170
-37
-18% -$648K
BEAT
29
DELISTED
BioTelemetry, Inc.
BEAT
$2.18M 0.94%
34,800
-8,000
-19% -$550K
CSII
30
DELISTED
Cardiovascular Systems, Inc.
CSII
$2.17M 0.94%
56,200
-10,000
-15% -$339K
MRSN
31
DELISTED
Mersana Therapeutics
MRSN
$2.12M 0.92%
+16,132
New +$2.03M
CRBP icon
32
Corbus Pharmaceuticals
CRBP
$166M
$2.12M 0.91%
10,167
+5,000
+97% +$1.1M
KDMN
33
DELISTED
Kadmon Holdings, Inc.
KDMN
$2M 0.86%
757,177
+691,677
+1,056% +$1.74M
NVRO
34
DELISTED
NEVRO CORP.
NVRO
$1.95M 0.84%
31,210
– –
SCYX icon
35
SCYNEXIS
SCYX
$48.1M
$1.92M 0.83%
15,912
– –
ARDX icon
36
Ardelyx
ARDX
$1.22B
$1.9M 0.82%
676,759
+203,900
+43% +$530K
ACHN
37
DELISTED
Achillion Pharmaceuticals
ACHN
$1.84M 0.79%
621,182
-9,000
-1% -$22.1K
DRNA
38
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$1.81M 0.78%
123,314
+4,814
+4% +$55.3K
ARQL
39
DELISTED
Arqule Inc
ARQL
$1.79M 0.77%
373,164
-84,500
-18% -$326K
VKTX icon
40
Viking Therapeutics
VKTX
$3.7B
$1.78M 0.77%
179,200
– –
VBIV
41
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$1.59M 0.69%
28,333
– –
AGTC
42
DELISTED
Applied Genetic Technologies Corporation
AGTC
$1.5M 0.65%
359,190
– –
JNJ icon
43
Johnson & Johnson
JNJ
$618B
$1.31M 0.57%
9,400
– –
ADXS
44
DELISTED
Advaxis Inc
ADXS
$1.2M 0.52%
202,222
+91,111
+82% +$518K
GNCA
45
DELISTED
Genocea Biosciences, Inc.
GNCA
$1.17M 0.51%
+248,707
New +$1.23M
NTUS
46
DELISTED
Natus Medical Inc
NTUS
$1.09M 0.47%
42,900
+5,000
+13% +$149K
ASMB icon
47
Assembly Biosciences
ASMB
$498M
$996K 0.43%
4,214
– –
DERM
48
DELISTED
Dermira, Inc.
DERM
$969K 0.42%
71,500
+61,500
+615% +$513K
INGN icon
49
Inogen
INGN
$175M
$944K 0.41%
+9,900
New +$1.23M
ALEC icon
50
Alector
ALEC
$168M
$918K 0.4%
+49,063
New +$928K
1
2
3 4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
WAS
Winch Advisory Services Appleton, Wisconsin $438M AUM 17.59% 1-Year Est. Return

DAFNA Capital Management's Q1 2019 Portfolio in Review

As of Q1 2019, DAFNA Capital Management held 89 positions worth $232M, up 15% from $201M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

DAFNA Capital Management withdrew a net $28.5M in Q1 2019, closing 10 positions and reducing 19 holdings. Its most notable exit was Loxo Oncology, Inc, an estimated $25.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 89% a quarter earlier, followed by Financials.

Against the trend, DAFNA Capital Management opened a new position in Mersana Therapeutics worth $2.12M.

  • DAFNA Capital Management's largest Q1 2019 buy was Mersana Therapeutics: 16,132 shares worth $2.12M.
  • DAFNA Capital Management added most to Wave Life Sciences in Q1 2019, an estimated $5.79M increase.
  • DAFNA Capital Management's biggest Q1 2019 reduction was Ascendis Pharma A/S, cutting an estimated $2.88M.
  • DAFNA Capital Management fully exited Loxo Oncology, Inc in Q1 2019, selling an estimated $25.4M.
  • DAFNA Capital Management's ten largest holdings make up 46% of its $232M portfolio in Q1 2019.
  • DAFNA Capital Management opened 6 new positions and closed 10 in Q1 2019.
  • DAFNA Capital Management's portfolio value rose 15% quarter-over-quarter to $232M.

Based on DAFNA Capital Management's 13F filing for Q1 2019, filed 15 May 2019.